# Sana Biotechnology *

**Canonical:** https://apis.io/providers/sana-biotechnology/  
**Website:** https://sana.com  
**APIs profiled:** 0

Sana Biotechnology is a clinical-stage biotechnology company (NASDAQ: SANA) focused on engineering cells as medicines. Its platforms repair or control genes inside cells and replace missing or damaged cells to address the underlying causes of disease, with drug candidates spanning type 1 diabetes, B-cell cancers, and B-cell-mediated autoimmune disorders. Surfaced as a portfolio company of gv and added to the API Evangelist network for enrichment. As of this enrichment pass Sana publishes no public API, developer portal, or technical documentation; this profile captures company identity and domain-security posture only.

## Kin Score — 10.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 10.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 4.8 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Sana Biotechnology Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Life Sciences, Biotechnology, Cell Therapy, Gene Therapy, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/sana-biotechnology/). Scores are computed from the provider's own public artifacts under a published rubric.